Página 1 desde 49 resultados
BACKGROUND OF THE INVENTION
The field of the invention relates to optical methods used for the screening and diagnosis of tissue abnormalities. In particular, the invention relates to the use of fluorescent spectroscopy to detect cancerous and precancerous tissues of the cervix.
Cervical cancer is
This application is based upon and claims the benefit of priority from Japanese patent application No. 2007-288563, filed on Nov. 6, 2007, the disclosure of which is incorporated herein in its entirety by reference.
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates
FIELD OF INVENTION
This invention relates to a simple screening test for colorectal cancer. Specifically, a method is described whereby a colorectal cancer marker is detected in rectal mucus obtained by digital rectal examination. More particularly, this marker is detected in the mucus deposited on
BACKGROUND OF INVENTION
1. Field of Invention
This invention relates to systems and methods for analyzing digital mammograms, and, more particularly, to systems and methods for performing a risk analysis and computer-aided diagnosis using digital mammography data.
2. Background
Breast composition, a
FIELD OF THE INVENTION
The present invention is related to the likelihood of the reoccurrence of cancer in a patient. More specifically, the present invention is related to the likelihood of the reoccurrence of cancer in a patient by minimizing false negatives and false positives.
BACKGROUND OF THE
FIELD OF THE INVENTION
This invention relates to detection of subcutaneous cellular mass utilizing optics and imaging techniques. More particularly, this invention is related to detecting (a) abnormal growth of tissues inside the body, (b) their types, (c) their dimensions, and (d) their location
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a national phase filing of International Patent Application No. PCT/EP2014/076143, filed Dec. 1, 2014, which claims priority to European Application No. 13195377.0, filed on Dec. 2, 2013, both of which are herein incorporated by reference
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a national phase filing of International Patent Application No. PCT/EP2014/076139, filed Dec. 1, 2014, which claims priority to European Application No. 13195377.0, filed on Dec. 2, 2013, both of which are herein incorporated by reference
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a national phase filing of International Patent Application No. PCT/EP2014/076141, filed Dec. 1, 2014, which claims priority to European Application No. 13195377.0, filed on Dec. 2, 2013, both of which are herein incorporated by reference
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a national phase filing of International Patent Application No. PCT/EP2014/076145, filed Dec. 1, 2014, which claims priority to European Application No. 13195377.0, filed on Dec. 2, 2013, both of which are herein incorporated by reference
This application is a National Stage of International Application PCT/EP2003/050096, filed Apr. 8, 2003, published Jan. 15, 2004, under PCT Article 21(2) in English; which claims the priority of EP 02007954.7, filed Apr. 9, 2002.
TECHNICAL FIELD
The present invention relates to a method for
TECHNICAL FIELD
The present invention relates to a method for discrimination of p16.sup.INK4a overexpressing metaplasias from neoplastic or preneoplastic p16.sup.INK4a overexpressing lesions by determination of the level of high risk HPV encoded gene-products such as e.g. HPV E2 or E7 molecules in
The present invention relates to a method for discrimination of p16.sup.INK4a overexpressing metaplasias from neoplastic or preneoplastic p16.sup.INK4a overexpressing lesions by determination of the level of high risk HPV encoded gene-products such as e.g. HPV E2 or E7 molecules in biological
The present invention relates to a method for discrimination of p16.sup.INK4a overexpressing metaplasias from neoplastic or preneoplastic p16.sup.INK4a overexpressing lesions by determination of the level of high risk HPV encoded gene-products such as e.g. HPV E2 or E7 molecules in biological
TECHNICAL FIELD
Embodiments herein relate to identification of cancer, and, more specifically, to methods and apparatus using magnetic resonance imaging for cancer identification.
BACKGROUND
Screening for breast cancer represents one of modern medicine's success stories. However, the continued large